The HIV-1 matrix protein p 17 can be efficiently delivered by intranasal route in mice using the TLR 2/6 agonist MALP-2 as mucosal adjuvant

被引：23

作者：

Becker, Pablo D.

Fiorentini, Simona

Link, Claudia

Tosti, Giorgio

Ebensen, Thomas

Caruso, Arnaldo

Guzman, Carlos A.

机构：

[1] GBF German Res Ctr Biotechnol, Dept Vaccinol, D-38124 Braunschweig, Germany

[2] Univ Brescia, Sch Med, Microbiol Sect, Dept Expt & Appl Med, I-25123 Brescia, Italy

来源：

VACCINE | 2006年 / 24卷 / 25期

关键词：

HIV-1; p17; MALP-2;

D O I：

10.1016/j.vaccine.2005.11.008

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The HIV-1 matrix protein p17 is a structural protein essential in the life cycle of HIV, by acting as a virokine/immunomodulator that supports viral replication and spreading. The presence of p17-specific antibodies and CTL responses correlates with slower progression to AIDS. Intranasal vaccination with p 17 and the TLR2/6 agonist MALP-2 stimulates strong humoral and cellular immune responses at systemic and mucosal levels. The antibodies blocked p17 binding to its receptor, which is a critical step for the exertion of its virokine activity. Our results suggest that p17 and MALP-2 are attractive candidates for incorporation in mucosal vaccines against HIV/AIDS. (c) 2005 Elsevier Ltd. All rights reserved.

引用

收藏

页码：5269 / 5276

页数：8

相关论文

共 37 条

[1] HIV-1 NEF LEADS TO INHIBITION OR ACTIVATION OF T-CELLS DEPENDING ON ITS INTRACELLULAR-LOCALIZATION [J].

BAUR, AS ;

SAWAI, ET ;

DAZIN, P ;

FANTL, WJ ;

CHENGMAYER, C ;

PETERLIN, BM .

IMMUNITY, 1994, 1 (05) :373-384

[2] Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant [J].

Borsutzky, S ;

Fiorelli, V ;

Ebensen, T ;

Tripiciano, A ;

Rharbaoui, F ;

Scoglio, A ;

Link, C ;

Nappi, F ;

Morr, M ;

Buttó, S ;

Cafaro, A ;

Mühlradt, PF ;

Ensoli, B ;

Guzmán, CA .

EUROPEAN JOURNAL OF IMMUNOLOGY, 2003, 33 (06) :1548-1556

[3] HIV-1 MATRIX PROTEIN P17 RESIDES IN CELL-NUCLEI IN ASSOCIATION WITH GENOMIC RNA [J].

BUKRINSKAYA, AG ;

VORKUNOVA, GK ;

TENTSOV, YY .

AIDS RESEARCH AND HUMAN RETROVIRUSES, 1992, 8 (10) :1795-1801

[4] A NUCLEAR-LOCALIZATION SIGNAL WITHIN HIV-1 MATRIX PROTEIN THAT GOVERNS INFECTION OF NONDIVIDING CELLS [J].

BUKRINSKY, MI ;

HAGGERTY, S ;

DEMPSEY, MP ;

SHAROVA, N ;

ADZHUBEI, A ;

SPITZ, L ;

LEWIS, P ;

GOLDFARB, D ;

EMERMAN, M ;

STEVENSON, M .

NATURE, 1993, 365 (6447) :666-669

[5] A neutralizing monoclonal antibody previously mapped exclusively on human immunodeficiency virus type 1 gp41 recognizes an epitope in p17 sharing the core sequence IEEE [J].

Buratti, E ;

Tisminetzky, SG ;

DAgaro, P ;

Baralle, FE .

JOURNAL OF VIROLOGY, 1997, 71 (03) :2457-2462

[6]

CHARGELEGUE D, 1995, CLIN EXP IMMUNOL, V99, P175, DOI 10.1111/j.1365-2249.1995.tb05529.x

[7] THE ROLE OF HELPER T-CELL PRODUCTS IN MOUSE B-CELL DIFFERENTIATION AND ISOTYPE REGULATION [J].

COFFMAN, RL ;

SEYMOUR, BWP ;

LEBMAN, DA ;

HIRAKI, DD ;

CHRISTIANSEN, JA ;

SHRADER, B ;

CHERWINSKI, HM ;

SAVELKOUL, HFJ ;

FINKELMAN, FD ;

BOND, MW ;

MOSMANN, TR .

IMMUNOLOGICAL REVIEWS, 1988, 102 :5-28

[8]

Cohen J, 2003, SCIENCE, V302, P1309

[9] HIV p17 enhances lymphocyte proliferation and HIV-1 replication after binding to a human serum factor [J].

De Francesco, MA ;

Caruso, A ;

Fallacara, F ;

Canaris, AD ;

Dima, F ;

Poiesi, C ;

Licenziati, S ;

Corulli, M ;

Martinelli, F ;

Fiorentini, S ;

Turano, A .

AIDS, 1998, 12 (03) :245-252

[10] HIV-1 matrix protein p17 increases the production of proinflammatory cytokines and counteracts IL-4 activity by binding to a cellular receptor [J].

De Francesco, MA ;

Baronio, M ;

Fiorentini, S ;

Signorini, C ;

Bonfanti, C ;

Poiesi, C ;

Popovic, M ;

Grassi, M ;

Garrafa, E ;

Bozzo, L ;

Lewis, GK ;

Licenziati, S ;

Gallo, RC ;

Caruso, A .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (15) :9972-9977

← 1 2 3 4 →